Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03223714 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT03223714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03223714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 24, 2016
Completion date
September 28, 2020
Enrollment
242 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

central retinal vein occlusion, macular edema